PACB analyst estimates
Pacific Biosciences (PACB) analyst ratings, the average price target and its range, and every firm's latest call.
PACB analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 23, 2026 | Stephens | PacBio price target raised to $2.50 from $1.50 at Stephens | $2.50 |
| Sep 9, 2026 | UBS | PacBio assumed with a Neutral at UBS | $1.35 |
| Apr 14, 2026 | Barclays | PacBio price target lowered to $1 from $1.50 at Barclays | $1.00 |
| Aug 8, 2025 | Bernstein | PacBio price target raised to $1.70 from $1.50 at Bernstein | $1.70 |
| Jun 25, 2025 | Barclays | PacBio price target lowered to $1.50 from $2 at Barclays | $1.50 |
| Jun 3, 2024 | Jefferies | Jefferies Starts Pacific Biosciences of California (PACB) at Buy | $4.00 |
| May 13, 2024 | Piper Sandler | PacBio price target lowered to $2 from $6.50 at Piper Sandler | $2.00 |
| May 13, 2024 | Morgan Stanley | PacBio price target lowered to $4 from $10 at Morgan Stanley | $4.00 |
| May 10, 2024 | Barclays | PacBio price target lowered to $2 from $3 at Barclays | $2.00 |
| Apr 18, 2024 | Goldman Sachs | Goldman Sachs Downgrades Pacific Biosciences of California (PACB) to Neutral | $2.50 |
| Apr 16, 2024 | Canaccord Genuity | PacBio price target lowered to $3.50 from $10 at Canaccord | $3.50 |
| Nov 16, 2022 | Canaccord Genuity | Canaccord Genuity Maintains Buy on Pacific Biosciences, Raises Price Target to $14 | $14.00 |
| Aug 17, 2022 | Piper Sandler | Pacific Biosciences price target raised to $7.50 from $6 at Piper Sandler | $7.50 |
| May 15, 2022 | Piper Sandler | Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler | $6.00 |
| Jan 12, 2022 | Piper Sandler | PacBio Stock (PACB): $20 Price Target From Piper Sandler | $20.00 |
- 3 firms rate PACB: 1 buy, 1 hold, 1 sell.
- The average price target is $1.93 from 2 analysts, from $1.35 to $2.50.
Updated 2026-11-03 00:01 UTC